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Abstract
Objective: Turnover of the extracellular matrix in all solid organs is governed mainly by a balance between the degrading
matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). An altered extracellular matrix metabolism has been
implicated in a variety of diseases. We investigated relations of serum levels of MMP-9 and TIMP-1 to mortality risk from an
etiological perspective.
Design: The prospective Uppsala Longitudinal Study of Adult Men (ULSAM) cohort, followed from 1991–1995 for up to 18.1
years. A random population-based sample of 1,082 71-year-old men, no loss to follow-up. Endpoints were all-cause
(n=628), cardiovascular (n=230), non-cardiovascular (n=398) and cancer mortality (n=178), and fatal or non-fatal
myocardial infarction (n=138) or stroke (n=163).
Results: Serum MMP-9 and TIMP-1 levels were associated with risk of all-cause mortality (Cox proportional hazard ratio [HR]
per standard deviation 1.10, 95% confidence interval [CI] 1.03–1.19; and 1.11, 1.02–1.20; respectively). TIMP-1 levels were
mainly related to risks of cardiovascular mortality and stroke (HR per standard deviation 1.22, 95% CI 1.09–1.37; and 1.18,
1.04–1.35; respectively). All relations except those of TIMP-1 to stroke risk were attenuated by adjustment for cardiovascular
disease risk factors. Relations in a subsample without cardiovascular disease or cancer were similar to those in the total
sample.
Conclusion: In this community-based cohort of elderly men, serum MMP-9 and TIMP-1 levels were related to mortality risk.
An altered extracellular matrix metabolism may be involved in several detrimental pathways, and circulating MMP-9 or
TIMP-1 levels may be relevant markers thereof.
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Introduction
In every part of the human body, the extracellular matrix plays an
important part as the framework of the parenchymal tissue. An
abnormal extracellular matrix regulation has been implicated as a
direct causal factor in a number of important disease processes, such as
cancer invasion and metastasis,[1] atherosclerotic plaque rupture,[2]
congestive heart failure development[3] and alveolar wall destruction
in chronic obstructive pulmonary disease.[4] The metabolism of the
extracellular matrix is governed by a balance between the degrading
matrix metalloproteinases (MMPs) and their tissue inhibitors
(TIMPs).[5] Some of these matrix markers are possible to measure
in serum or plasma, thus the possibility of monitoring matrix turnover
b ym e a n so fs i m p l eb l o o dt e s t si sa na l l u r i n gc o n c e p t .
Two of the matrix markers most consistently indicted in
cardiovascular disease development and prognosis are MMP-9
and TIMP-1.[6] Circulating levels of these have been related to
most cardiovascular disease risk factors in large community-based
samples[7,8,9,10] and have been associated with risk of death in
patients with known cardiovascular disease.[11,12,13] In studies of
limited sample sizes, higher circulating MMP-9 and TIMP-1 levels
have also indicated worse prognosis in several cancer types,
including lung[14] and breast cancer,[15] and higher circulating
TIMP-1 levels have also portended worse prognosis in colorec-
tal[16] and gastric cancer.[17]
Relations of circulating MMP-9 and TIMP-1 levels to mortality
risk in the general population are little known. We aimed to study
relations of MMP-9 and TIMP-1 levels to risk of cause-specific
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16185mortality and cardiovascular events from an etiological perspec-
tive, in a well-characterized community-based cohort of elderly
men.
Methods
Ethics Statement
All participants gave written consent, and the Uppsala
University ethics committee approved the study.
Study Sample
We used the Uppsala Longitudinal Study of Adult Men
(ULSAM), a prospective cohort study to which all 50-year-old
men living in Uppsala County, Sweden, in 1970–1973 were invited
(www.pubcare.uu.se/ULSAM). Out of 2,841 invited, 2,322 accept-
ed. The cohort was re-examined at circa age 60 and age 71, the
latter examination (in 1991–1995) defining the baseline cohort of
the present study. Of the 1,681 71-year-old men alive, 1,221 (73%)
participated. A further 100 men were excluded because of lack of
matrix biomarker measurements, and another 39 due to lacking
covariates, rendering a sample of 1,082 men eligible for the present
study. A subsample of 818 men without cardiovascular disease
(myocardial infarction [ICD-9 code 410, ICD-10 code I21], stroke
[ICD-9 codes 430–433 & 436; ICD-10 codes I60–I64], heart failure
[chart review-validated cases], or electrocardiographic Q-waves or
left bundle-branch block [Minnesota codes 1.1 and 7.1]) or cancer
(ICD-9 codes 140–209; ICD-10 codes C00–C99) was also
investigated in order to minimize influence of reverse causation.
Baseline Investigations
At the age 71 examination, all participants answered self-
administered questionnaires, underwent a medical examination,
blood sampling after an overnight fast, supine blood pressure
measurements, and anthropometric measurements as described
previously. [18]
Smoking experience was classified into four levels: never
smoking, current smoking, or two levels of previous smoking
(above or below median [33] of pack-years of previous smoking).
Diabetes at baseline was defined as fasting plasma glucose .=7.0
mmol/L or use of oral hypoglycemic agents or insulin. Office
systolic and diastolic blood pressures were measured twice in the
right arm to the nearest even number with the subject in the
supine position after resting for 10 minutes, and the means of the
two measurements were used. Use of antihypertensive or lipid-
lowering drugs was classified using questionnaires. Cholesterol
concentration was analyzed by an enzymatic technique. High
sensitivity C-reactive protein and cystatin C were measured using
latex enhanced reagent (Dade Behring, Deerfield, IL, USA) using
a Behring BN ProSpec analyzer (Dade Behring). Glomerular
filtration rate was estimated from serum cystatin C by the formula
eGFR =77.24*[cystatin C]-1.2623.
MMP-9 and TIMP-1 were measured in fasting serum samples
frozen shortly after sampling and then stored in -70 degrees C
awaiting analysis. The samples were thawed and analyzed in early
2007 using commercial ELISA assays provided by R&D Systems
Europe Ltd (Abingdon, United Kingdom). The samples had when
thawed been frozen for a mean of 13.5 years (extremes 11.6–15.4
years), herein denoted ‘‘freezer time’’.
Follow-Up and Outcome Parameters
For the primary outcome, all-cause mortality, participants were
followed from the baseline examination in 1991–1995 to October
4
th, 2009, with a maximum of 18.1 years of follow-up (median 14.7
years;13,682person-yearsat risk).Forall otheroutcomes,follow-up
data was available until December 31, 2007, rendering up to 16.4
years of follow-up. We investigated six outcomes: all-cause
mortality; cardiovascular mortality (ICD-9 codes 390–459; ICD-
10 codes I00-I99); non-cardiovascular mortality (all other deaths);
cancer mortality (ICD-9 codes 140–209; ICD-10 codes C00-C99);
fatal or non-fatal myocardial infarction (ICD-9 code 410, ICD-10
code I21); and fatal or non-fatal stroke (ICD-9 codes 430–433 &
436; ICD-10 codes I60–I64). The primary outcome was defined
using the Swedish census registry, which is updated within a few
days after a person’s death. All other outcomes were defined using
the Swedish national Cause-of-Death and In-Patient registries,
which are updated yearly with some lag. All three data sources
include all Swedish citizens, and none of the study participants
emigrated during follow-up; therefore we had zero loss to follow-up.
Statistical Analysis
Initially, distributional properties of all variables were examined
(Figures S1 and S2). We thereafter examined relations of MMP-9
and TIMP-1 to the six outcomes (all-cause mortality, CVD
mortality, non-CVD mortality, cancer mortality, fatal or non-fatal
myocardial infarction, and fatal or non-fatal stroke), each matrix
biomarker and outcome in a separate set of models, using Cox
proportional hazards analyses.
We investigated relations per standard deviation (SD) and by
quartiles of MMP-9 and TIMP-1 to all outcomes. Freezer time
was a priori decided upon as a covariate in all models, as the
effects of long-term freezing on these biomarkers is not known.
Both MMP-9 (r=0.07, p=0.02) and TIMP-1 (r=20.10,
p=0.002) levels were statistically significantly albeit weakly related
to freezer time. Age was adjusted for in all models by using age as
the timeline. We considered three sets of models, in a hierarchical
fashion: A) models adjusted for age and freezer time; B) models
additionally adjusted for systolic blood pressure, antihypertensive
treatment, lipid-lowering treatment, diabetes mellitus, body mass
index, total cholesterol, estimated glomerular filtration rate, and
smoking status; and C) models additionally adjusted for C-reactive
protein (because inflammation has been identified as an important
MMP stimulus). Model A is the primary model, and models B and
C are viewed as mechanistic models – if substantial parts of the
effects of cardiovascular disease risk factors or inflammation on
risk are mediated by matrix remodeling (as reflected in altered
levels of matrix markers), the matrix marker estimates will be lower
in these models than in models A.
Schoenfeld’s tests and inspection of Schoenfeld residuals and
Nelson-Aalen curves were used to confirm proportionality of
hazards, and Martingale residuals and multivariable-regression
spline models with 5 degrees of freedom for the matrix markers
were inspected to rule out deviations from linearity, in models A
and B. We investigated additive interactions between the matrix
markers (4
th vs. 1
st quartiles) and the covariates by calculating the
relative excess risk due to interaction (RERI),[19] and multipli-
cative interactions between the matrix markers (on their
continuous scale) and the covariates were tested using product
terms. Stata 10.1 was used for all calculations.
Results
Clinical characteristics of the study sample at baseline are
presented in Table 1.
During follow-up for all-cause mortality, 628 of the 1,082 men
in the total sample died (rate 45.9/1,000 person-years at risk).
During follow-up for cause-specific mortality and cardiovascular
events, 230 died from cardiovascular disease and 178 of cancer
(Table 2).
MMP-9 and TIMP-1 and Mortality Risk
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MMP-9 and TIMP-1 in the total sample is displayed in Figures 1
and 2. Relations of both MMP-9 and TIMP-1 to all-cause
mortality were observed (Table 3). The notion of essentially linear
relations was supported by analyses by quartiles of MMP-9 and
TIMP-1 in Figures 1 and 2 and Figure S3 (and was confirmed by
spline analyses and inspection of Martingale residuals).
The relation of MMP-9 level to all-cause mortality risk appeared
to be driven by a relation to non-cardiovascular mortality risk, but
not to cancer mortality risk. These relations were attenuated upon
adjustment for covariates in models B and C (Table 3).
The relation of TIMP-1 level to all-cause mortality risk was
driven by a relation to cardiovascular mortality risk. The relation
to all-cause mortality risk was slightly attenuated by adjustment for
covariates in model B, and more so by further adjustment for C-
reactive protein. TIMP-1 level was most robustly related to risk of
stroke. The relation to stroke risk was not affected by adjustment
for covariates, including C-reactive protein (Table 3).
Relations of matrix biomarkers to outcomes in the subsample
without cardiovascular disease or cancer were similar to those in
the total sample (Table 3). Relations of TIMP-1 level to risks of
cardiovascular mortality and stroke were slightly stronger in this
subsample than in the total sample. The relation to cardiovascular
mortality risk was less affected by adjustment for covariates in the
subsample than in the total sample (Table 3).
Assumptions of proportionality of hazards were met. No
interactions with any of the covariates were observed. Relations
of covariates to risk of outcomes in the total sample are displayed
in Table S1.
Discussion
The primary observation in this community-based sample of
men was that higher levels of circulating MMP-9 or TIMP-1 were
associated with higher risk of death. Higher TIMP-1 levels were
mainly related to higher risk of stroke and cardiovascular
mortality, and higher MMP-9 levels mainly to risk of non-
cardiovascular mortality. The observed relations were of modest
magnitude, and the relations of TIMP-1 to stroke risk were not
explained to any major extent by established cardiovascular
disease risk factors or C-reactive protein.
Comparisons with Previous Studies
Earlierstudies ofassociationsoflevelsofcirculatingbiomarkers of
extracellular matrix turnover with mortality risk have so far mainly
been made in groups of patients with manifest cardiovascular
disease or cancer. In previous studies of patients withatherosclerotic
cardiovascular disease, TIMP-1 has been observed to predict
cardiovascular[11,12] and all-cause mortality[11] and cardiovascu-
lar events,[20] and MMP-9 has been associated with risk of
cardiovascular death in one study[13] and a combined endpoint of
stroke or cardiovascular death in another,[21] but no relation was
observed in one study.[11] In one study of men, TIMP-1 was not
related to prognosis,[22] and in another population-based study
selected based on left ventricular geometry and with limited number
of cases, TIMP-1 was related to mortality risk but not risk of
cardiovascular events, and MMP-9 measured with an assay with
limited sensitivity was not related to any outcome.[23] Studies in
samples of heart failure patients have been inconsistent, with reports
Table 1. Characteristics at Baseline.
Total Sample (n=1,082) Subsample without CVD or cancer (n=818)
Clinical Variables
Age, years 71.0 (0.6) 71.0 (0.6)
Diabetes mellitus 188 (17.3) 131 (16.0)
Hypertension 807 (74.6) 600 (73.4)
Systolic blood pressure, mmHg 147 (18) 148 (19)
Diastolic blood pressure, mmHg 84 (10) 84 (9)
Antihypertensive treatment 387 (35.8) 249 (30.4)
Current smoking 236 (21.8) 179 (21.9)
Never-smoking 335 (31.0) 249 (30.4)
Low previous smoking 377 (34.8) 226 (27.6)
High previous smoking 370 (34.2) 164 (20.1)
Waist circumference, cm 94.7 (9.6) 94.4 (9.5)
Body mass index, kg/m
2 26.2 (3.4) 26.1 (3.4)
s-Cholesterol, mmol/L 5.80 (0.98) 5.79 (0.99)
s-HDL-cholesterol, mmol/L 1.28 (0.35) 1.30 (0.35)
s-Triglycerides, mmol/L 1.28 (0.78) 1.22 (0.79)
Lipid lowering treatment 100 (9.7) 66 (8.5)
Estimated glomerular filtration rate, mL/min 74.3 (14.8) 93.4 (19.0)
s-C-reactive protein, mg/L 3.4 (4.9) 3.3 (4.7)
Matrix Biomarkers
s-MMP-9, ng/L 332 (234) 332 (236)
s-TIMP-1, ng/L 200 (71) 199 (73)
Data are numbers (percent) or means (standard deviations), and medians (interquartile ranges) for triglycerides, MMP-9 and TIMP-1. HDL, high-density lipoprotein; MMP-
9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of metalloproteinases-1.
doi:10.1371/journal.pone.0016185.t001
MMP-9 and TIMP-1 and Mortality Risk
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16185of relations of these markers with prognosis in some[24] but not
other studies.[25] MMP-9 level has been related to more severe
neurological deficits[26] and increased risk of hemorrhagic
transformation of infarcts in stroke patients[27,28,29], but relations
of TIMP-1 to stroke outcomes are unknown. Relations of these
markers to incident stroke risk in the general population are also
unknown. In one recent large nested case-control study, relations of
MMP-9 to myocardial infarction and stroke were observed in
unadjusted models, but not in multivariable-adjusted ones.[30]
The present study is in line with previous observations in patient
samples of associations of TIMP-1 with all-cause and cardiovas-
cular mortality, but extends these to a population-based setting
and identifies a robust relation to stroke risk. The weaker
associations of MMP-9 than TIMP-1 levels to cardiovascular
mortality in the present study are also in line with the previous
literature, but are now demonstrated in the general population.
Results of studies in small samples of cancer patients have been
inconsistent, but higher circulating MMP-9 and TIMP-1 levels
have indicated worse prognosis in studies of several cancer
types.[14,15,16,17] No previous studies have reported associations
of levels of matrix biomarkers to cancer incidence. The present
study does not support strong such associations for major cancer
types, but cannot exclude modest relations or relations to less
frequent cancer types.
Table 2. Numbers of Events and Incidence Rates.
Outcome Person-years at risk Number of events
Incidence rate (95% confidence interval)
per 1,000 person-years at risk
Total Sample (n=1,082)
All-cause mortality 13,682 628 45.9 (42.4–49.6)
CVD mortality 12,792 230 18.0 (15.8–20.5)
Non-CVD-mortality 12,792 398 31.1 (28.2–34.3)
Cancer mortality 12,792 178 13.9 (12.0–16.1)
Myocardial infarction 11,272 138 12.2 (10.4–14.5)
Stroke 11,802 163 13.8 (11.8–16.1)
Subsample without CVD or cancer (n=818)
All-cause mortality 10,746 435 40.5 (36.8–44.5)
CVD mortality 10,000 151 15.1 (12.9–17.7)
Non-CVD-mortality 10,000 284 28.4 (25.3–31.9)
Cancer mortality 10,000 120 12.0 (10.0–14.4)
Myocardial infarction 9,547 107 11.2 (9.3–13.5)
Stroke 9,529 122 12.8 (10.7–15.3)
CVD, cardiovascular disease.
doi:10.1371/journal.pone.0016185.t002
Figure 1. All-Cause Mortality by Quartiles of s-MMP-9. Quartile (Q) limits for matrix metalloproteinase-9 (MMP-9) were 228, 332 and 462 ng/L.
doi:10.1371/journal.pone.0016185.g001
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Relations of TIMP-1 to cardiovascular disease risk may have a
variety of explanations. TIMP-1 is the main inhibitor of MMP-9,
but also inhibits several other MMPs. Discrepant findings between
MMP-9 and TIMP-1 is therefore not unexpected.
The investigated proteins may be causally involved in
atherosclerosis development. In experimental settings, increased
TIMP-1 expression has led to decreased atherosclerosis develop-
ment in some[31–32] but not other studies,[33] and decreased
MMP-9 expression has also led to a reduced atherosclerotic
burden.[34]
MMP-9 and TIMP-1 may also be causally involved in cardiac
dysfunction. In animal models of heart failure of different origin,
pharmacological MMP inhibition reduces left ventricular dilata-
tion and preserves cardiac systolic function[35,36] and transgenic
animal models also support the notion of detrimental effects of
MMP-9 and beneficial effects of TIMP-1 after myocardial
infarction.[37,38] In general population-based samples, circulating
Figure 2. All-Cause Mortality by Quartiles of s-TIMP-1. Quartile (Q) limits for tissue inhibitor of metalloproteinases-1 (TIMP-1) were 166, 200
and 238 ng/L.
doi:10.1371/journal.pone.0016185.g002
Table 3. Relations of Matrix Biomarkers to Risk of Cause-Specific Mortality and Cardiovascular Events.
Matrix metalloproteinase-9 Tissue inhibitor of metalloproteinases-1
Models A Models B Models C Models A Models B Models C
Total Sample (n=1,082)
All-cause mortality 1.10 (1.03–1.19) 1.03 (0.95–1.12) 1.00 (0.91–1.08) 1.11 (1.02–1.20) 1.09 (1.00–1.19) 1.06 (0.97–1.17)
CVD mortality 1.09 (0.97–1.23) 0.99 (0.87–1.13) 0.97 (0.84–1.11) 1.22 (1.09–1.37) 1.13 (0.98–1.30) 1.10 (0.96–1.27)
Non-CVD mortality 1.11 (1.02–1.22) 1.06 (0.96–1.18) 1.02 (0.92–1.14) 1.04 (0.93–1.16) 1.07 (0.95–1.20) 1.05 (0.93–1.18)
Cancer mortality 1.08 (0.94–1.24) 1.02 (0.87–1.19) 0.95 (0.80–1.13) 1.10 (0.95–1.27) 1.15 (0.98–1.34) 1.11 (0.94–1.30)
Myocardial infarction 0.98 (0.83–1.17) 0.91 (0.76–1.09) 0.88 (0.72–1.06) 1.14 (0.98–1.33) 1.17 (0.98–1.39) 1.14 (0.96–1.36)
Stroke 1.00 (0.86–1.17) 0.95 (0.80–1.12) 0.92 (0.77–1.10) 1.18 (1.04–1.35) 1.20 (1.03–1.39) 1.18 (1.01–1.38)
Subsample without CVD or cancer (n=818)
All-cause mortality 1.14 (1.04–1.25) 1.07 (0.97–1.18) 1.04 (0.94–1.16) 1.10 (1.00–1.21) 1.11 (1.00–1.24) 1.09 (0.98–1.22)
CVD mortality 1.14 (0.97–1.33) 1.02 (0.86–1.21) 1.00 (0.84–1.20) 1.25 (1.10–1.42) 1.21 (1.03–1.42) 1.19 (1.00–1.40)
Non-CVD mortality 1.14 (1.02–1.28) 1.11 (0.98–1.26) 1.07 (0.94–1.23) 1.02 (0.89–1.16) 1.07 (0.93–1.23) 1.05 (0.90–1.21)
Cancer mortality 1.13 (0.95–1.34) 1.07 (0.88–1.31) 1.01 (0.82–1.26) 1.10 (0.93–1.31) 1.18 (0.98–1.43) 1.15 (0.94–1.40)
Myocardial infarction 1.06 (0.87–1.28) 0.97 (0.79–1.19) 0.94 (0.76–1.17) 1.16 (0.98–1.37) 1.20 (0.99–1.45) 1.18 (0.97–1.44)
Stroke 0.91 (0.74–1.12) 0.85 (0.68–1.06) 0.81 (0.64–1.03) 1.20 (1.03–1.38) 1.23 (1.05–1.44) 1.21 (1.03–1.43)
Data are Cox proportional hazard ratios (95% confidence intervals) per 1-standard deviation of the matrix biomarker. Models A adjusted for age and freezer time;
models B additionally adjusted for systolic blood pressure, antihypertensive treatment, lipid-lowering treatment, diabetes mellitus, body mass index, total cholesterol,
estimated glomerular filtration rate, and smoking status; models C additionally adjusted for C-reactive protein. CVD, cardiovascular disease.
doi:10.1371/journal.pone.0016185.t003
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hypertrophy,[7,8,9] and TIMP-1 levels inversely to left ventricular
systolic function.[7,8] One mechanism behind the relations to
heart failure development may be intracellular cleaving of myosin
filaments by MMP-9.[39] The sources of the matrix markers in
this study are unknown, but relations of circulating and
myocardial levels of some matrix markers are substantial.[6]
One explanation behind the observed robust relations of TIMP-
1 to stroke risk may be that higher TIMP-1 levels signify higher left
ventricular mass.[7,8] Left ventricular hypertrophy is a powerful
risk factor for stroke, possibly because it may lead to atrial
fibrillation.
Explanations behind the observed relation of MMP-9 to non-
cardiovascular death are less substantiated. The matrix markers
were not important risk factors for cancer mortality in the present
study, but previous associations of these markers with prognosis in
patients with malignant disease have been explained by an MMP-
independentgrowth-promotingcapacityofTIMP-1,[40]andeffects
of MMP-9 on tumor growth, metastasis and angiogenesis.[41]
MMP-9 has been demonstrated to regulate leukocyte function
through a number of mechanisms, including activation of pro-IL-
1b into IL-1b and truncation of IL-8 into a more active form and,
as degranulation of MMP-9 from neutrophils is stimulated by IL-
8, thus creating a positive feedback loop.[42] MMP-9 may
therefore potentially play a role in the course of infectious diseases;
and possibly in pulmonary disease.
Altered extracellular matrix turnover is a known cause of
osteoporosis and fractures, which in some cases can lead to
fatalities. This could also explain part of the non-cardiovascular
mortality.
All relations of MMP-9 to outcomes were attenuated by
adjustment for covariates, which is consistent with the notion that
MMP-9 levels may be on a causal pathway between the covariates
and the outcomes. Relations of TIMP-1 level to stroke risk were
independent of these covariates. The discrepancy between
relations of MMP-9 and TIMP-1 to cardiovascular events was
not just due to differences in measurement precision, as the point
estimates were lower for MMP-9 relations. The fact that TIMP-1
is the inhibitor also of other MMPs than MMP-9 (notably MMP-
1), and these MMPs may also be important in the pathophysiology
of cardiovascular disease, may partly explain why TIMP-1 was a
stronger marker than MMP-9 of cardiovascular disease risk in this
and other studies.
Inflammation is a known trigger of MMP expression and
secretion. The observation that the relation of TIMP-1 to stroke
risk was independent of C-reactive protein levels, as well as other
cardiovascular risk factors, may indicate that extracellular matrix
metabolism is an important process per se. Similarly, TIMP-1
predicted cardiovascular events independently of C-reactive
protein, interleukin-6 and white cell count in another study of a
patient sample.[20] Extracellular matrix metabolism should
therefore be viewed as an entity separate from cytokine-mediated
inflammation, and its best measurement and prognostic value
determined.
Strengths and Limitations
Strengths of this study include the prospective cohort design, the
relatively large number of participants, and the general population
sample. The most obvious limitation is that it only comprises
elderly men. Generalizability to women, younger persons, and
non-Caucasians is unknown. Possible pre-analytical errors of
TIMPs and MMPs have been a matter of debate. Falsely elevated
serum levels due to release from leukocytes and thrombocytes
during handling have been suggested.[43] On the other hand, this
release may be a physiologically important property. One study
reported decreasing levels of MMP-9, but not TIMP-1, in plasma
over time in spite of frozen storage,[44] but the effects of freezing
on serum levels are unknown. In this study, we accounted for time
in the freezer in all statistical analyses. Because a smorgasbord of
different MMPs and TIMPs exist, other MMP and TIMP species
than the ones studied may be important. The cause of death is
based on national registry data, and misclassification between
causes of death is possible, but likely random. The investigation of
multiple outcomes and multiple models is motivated in an
etiological analysis such as the present, but may increase the risk
of type-I error.
Conclusions
In this study, higher levels of circulating MMP-9 or TIMP-1
were associated with higher risk of death. In particular, higher
TIMP-1 levels were related to higher risk of stroke and
cardiovascular death.
An altered extracellular matrix metabolism is indicted in several
detrimental pathways. Based on these observations, the most
important of these pathways from a mortality perspective may be
primarily cardiovascular disease-related ones. Circulating MMP-9
or TIMP-1 levels may be promising markers of those matrix
metabolism alterations. We encourage investigation of these
associations in other general population samples, and investigation
of relations of other markers of extracellular matrix metabolism to
hard endpoints in the general population. This is a novel group of
mortality risk factors reflecting pathways for which development of
drugs is ongoing.[45] Before such drugs can be useful in clinical
practice, tools for identification of target groups and for
monitoring treatment need to be developed. Our findings may
be an important step in that direction.
Supporting Information
Figure S1 Distribution of s-MMP-9.
(TIF)
Figure S2 Distribution of s-TIMP-1.
(TIF)
Figure S3 Relations of Quartiles of Matrix Biomarkers
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